Nuevolution AB (publ) announces timing for the third quarter release and webcast
Stockholm, 10 May 2017 – Nuevolution AB (publ) (NUE.ST) announces today that it will report its third quarter 2016/17 financial results on Wednesday 17 May at 8:30 CET.
On Wednesday 17 May at 14:00 CET, the company’s executive management will host a conference call and webcast presentation of the results and provide an update on partnering activities and pipeline programs. Access to the event can be obtained as follows:
LIVE access on Wednesday 17 May at 14:00 CET
Telephone numbers:
SE: +46 85 664 2692
DK: +45 3544 5575
UK: +44 20 3008 9802
US: +1 855 831 5948
Webcast available at www.nuevolution.com in the Investors section and at www.financialhearings.com
REPLAY access
Webcast replay will be available on Nuevolution’s website at www.nuevolution.com in the Investors section and at www.financialhearings.com
For more information, please contact:
Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Email: ahg@nuevolution.com
Henrik Damkjær Simonsen, CFO
Phone: +45 3913 0947
Email: hs@nuevolution.com
Information about Nuevolution AB (publ)
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was sent for publication on Wednesday 10 May 2017 at 11:00 CET.
Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com
Tags: